Transcend Discloses 2.6% IN8bio Stake — 107,416 Shares Reported
Rhea-AI Filing Summary
This Amendment No. 2 to a Schedule 13G discloses that Transcend Partners Opportunity Fund I LLC beneficially owns 107,416 shares of IN8bio common stock, representing 2.6% of the class. The percentage is calculated using 4,078,139 shares outstanding as reported as of June 30, 2025. The Reporting Person reports no sole voting or sole dispositive power and instead reports shared voting and shared dispositive power over the shares. Actions regarding these shares require a majority vote of Transcend's managing members, each of whom disclaims beneficial ownership. The amendment is a disclosure of beneficial ownership rather than an indication of control.
Positive
- None.
Negative
- None.
Insights
TL;DR Holding of 107,416 shares (2.6%) is a modest, disclosed stake with shared — not sole — control, a neutral ownership update for investors.
The statement reports a 2.6% beneficial position based on 4,078,139 shares outstanding and specifies that the Reporting Person holds shared voting and dispositive power while reporting no sole powers. For investors, the size of the stake is below 5% and the governance mechanics restrict unilateral action, making this a compliance disclosure with limited immediate market impact.
TL;DR Shared control through managing members and disclaimers suggests the position does not signal a control attempt and has limited governance influence.
The filing clarifies that voting and disposition require a majority of Transcend's managing members and that those managers disclaim beneficial ownership. This structure indicates internal allocation of decision rights within the Reporting Person rather than direct, individual control. As an amendment to a Schedule 13G, the disclosure enhances transparency about who holds collective authority but does not, by itself, evidence a change in issuer control.